Jack Allen
Stock Analyst at Robert W. Baird
(0.04)
# 4,677
Out of 4,690 analysts
332
Total ratings
29.3%
Success rate
-16.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintained: Buy | $12 → $15 | $5.77 | +159.97% | 27 | Jun 30, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $57 | $33.84 | +68.44% | 1 | Jun 26, 2026 | |
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $49 | $14.53 | +237.23% | 1 | May 1, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $7 → $13 | $12.87 | +1.01% | 25 | Apr 27, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Buy | $7 → $9 | $2.02 | +345.54% | 23 | Apr 14, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $47 → $40 | $25.61 | +56.19% | 12 | Feb 13, 2026 | |
| TIL Instil Bio | Downgraded: Hold | $180 → $7 | $7.58 | -7.65% | 28 | Jan 7, 2026 | |
| MREO Mereo BioPharma Group | Maintained: Buy | $8 → $1 | $0.2525 | +296.04% | 5 | Dec 29, 2025 | |
| VOR Vor Biopharma | Maintained: Buy | $64 → $46 | $22.65 | +103.09% | 29 | Dec 23, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintained: Hold | $52 → $44 | $57.72 | -23.77% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.11 | +350.45% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $6 | $3.16 | n/a | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.54 | n/a | 27 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4 | $2.43 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0013 | n/a | 14 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.43 | n/a | 17 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $84 | $36.62 | n/a | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.40 | n/a | 26 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $72 → $65 | $64.67 | n/a | 9 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $27 | $15.03 | n/a | 17 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $200 → $25 | $12.91 | n/a | 9 | Sep 26, 2023 |
Taysha Gene Therapies
Jun 30, 2026
Maintained: Buy
Price Target: $12 → $15
Current: $5.77
Upside: +159.97%
Faeth Therapeutics
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $57
Current: $33.84
Upside: +68.44%
Lyell Immunopharma
May 1, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $14.53
Upside: +237.23%
Intellia Therapeutics
Apr 27, 2026
Maintained: Hold
Price Target: $7 → $13
Current: $12.87
Upside: +1.01%
Allogene Therapeutics
Apr 14, 2026
Maintained: Buy
Price Target: $7 → $9
Current: $2.02
Upside: +345.54%
Ultragenyx Pharmaceutical
Feb 13, 2026
Maintained: Buy
Price Target: $47 → $40
Current: $25.61
Upside: +56.19%
Instil Bio
Jan 7, 2026
Downgraded: Hold
Price Target: $180 → $7
Current: $7.58
Upside: -7.65%
Mereo BioPharma Group
Dec 29, 2025
Maintained: Buy
Price Target: $8 → $1
Current: $0.2525
Upside: +296.04%
Vor Biopharma
Dec 23, 2025
Maintained: Buy
Price Target: $64 → $46
Current: $22.65
Upside: +103.09%
CRISPR Therapeutics AG
Nov 11, 2025
Maintained: Hold
Price Target: $52 → $44
Current: $57.72
Upside: -23.77%
Sep 23, 2025
Reiterated: Buy
Price Target: $5
Current: $1.11
Upside: +350.45%
Aug 13, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $3.16
Upside: n/a
Jul 17, 2025
Reiterated: Buy
Price Target: $18
Current: $3.54
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $5 → $4
Current: $2.43
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $0.0013
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $11.43
Upside: n/a
Nov 6, 2024
Maintained: Buy
Price Target: $84
Current: $36.62
Upside: n/a
Nov 5, 2024
Maintained: Buy
Price Target: $10
Current: $3.40
Upside: n/a
Oct 30, 2024
Maintained: Hold
Price Target: $72 → $65
Current: $64.67
Upside: n/a
Nov 16, 2023
Maintained: Hold
Price Target: $27
Current: $15.03
Upside: n/a
Sep 26, 2023
Downgraded: Hold
Price Target: $200 → $25
Current: $12.91
Upside: n/a